Mehrdad Hefazi1, Mark R Litzow2. 1. Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. 2. Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. litzow.mark@mayo.edu.
Abstract
PURPOSE OF REVIEW: This article provides an overview of the current knowledge regarding the biology and treatment of T cell acute lymphoblastic leukemia (T-ALL) and highlights the most recent findings in this field over the past 5 years. RECENT FINDINGS: Remarkable progress has been made in the genomic landscape of T-ALL over the past few years. The discovery of activating mutations of NOTCH1 and FBXW7 in a majority of patients has been a seminal observation, with several early phase clinical trials currently exploring these as potential therapeutic targets. Characterization of early T cell precursor ALL, incorporation of minimal residual disease assessment into therapeutic protocols, and use of pediatric-intensive regimens along with judicious use of allogeneic HCT have significantly improved risk stratification and treatment outcomes. Improved risk stratification and the use of novel targeted therapies based on recent genomic discoveries are expected to change the therapeutic landscape of T-ALL and hopefully improve the outcomes of this historically poor prognosis disease.
PURPOSE OF REVIEW: This article provides an overview of the current knowledge regarding the biology and treatment of T cell acute lymphoblastic leukemia (T-ALL) and highlights the most recent findings in this field over the past 5 years. RECENT FINDINGS: Remarkable progress has been made in the genomic landscape of T-ALL over the past few years. The discovery of activating mutations of NOTCH1 and FBXW7 in a majority of patients has been a seminal observation, with several early phase clinical trials currently exploring these as potential therapeutic targets. Characterization of early T cell precursor ALL, incorporation of minimal residual disease assessment into therapeutic protocols, and use of pediatric-intensive regimens along with judicious use of allogeneic HCT have significantly improved risk stratification and treatment outcomes. Improved risk stratification and the use of novel targeted therapies based on recent genomic discoveries are expected to change the therapeutic landscape of T-ALL and hopefully improve the outcomes of this historically poor prognosis disease.
Entities:
Keywords:
Early T cell precursor acute lymphoblastic leukemia; Minimal residual disease; Nelarabine; T cell acute lymphoblastic leukemia; Targeted therapies
Authors: Piotr Kozlowski; Maria Åström; Lucia Ahlberg; Per Bernell; Erik Hulegårdh; Hans Hägglund; Karin Karlsson; Alicja Markuszewska-Kuczymska; Beata Tomaszewska-Toporska; Bengt Smedmyr; Rose-Marie Amini; Helene Hallböök Journal: Eur J Haematol Date: 2014-02-21 Impact factor: 2.997
Authors: Sofie Peirs; Joni Van der Meulen; Inge Van de Walle; Tom Taghon; Frank Speleman; Bruce Poppe; Pieter Van Vlierberghe Journal: Immunol Rev Date: 2015-01 Impact factor: 12.988
Authors: Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana Journal: Lancet Oncol Date: 2009-01-13 Impact factor: 41.316
Authors: S J Lauer; D Pinkel; G R Buchanan; P Sartain; J M Cornet; R Krance; L D Borella; J T Casper; L E Kun; R G Hoffman Journal: Cancer Date: 1987-11-15 Impact factor: 6.860
Authors: Robert J Hayashi; Stuart S Winter; Kimberly P Dunsmore; Meenakshi Devidas; Zhiguo Chen; Brent L Wood; Michelle L Hermiston; David T Teachey; Sherrie L Perkins; Rodney R Miles; Elizabeth A Raetz; Mignon L Loh; Naomi J Winick; William L Carroll; Stephen P Hunger; Megan S Lim; Thomas G Gross; Catherine M Bollard Journal: J Clin Oncol Date: 2020-06-17 Impact factor: 44.544
Authors: Alberto M Parra-Perez; Amalia Pérez-Jiménez; Isabel Gris-Cárdenas; Gloria C Bonel-Pérez; Luis M Carrasco-Díaz; Khalida Mokhtari; Leticia García-Salguero; José A Lupiáñez; Eva E Rufino-Palomares Journal: Int J Mol Sci Date: 2022-06-24 Impact factor: 6.208
Authors: Małgorzata Dawidowska; Roman Jaksik; Monika Drobna; Bronisława Szarzyńska-Zawadzka; Maria Kosmalska; Łukasz Sędek; Ludomiła Machowska; Anna Lalik; Monika Lejman; Marek Ussowicz; Krzysztof Kałwak; Jerzy R Kowalczyk; Tomasz Szczepański; Michał Witt Journal: Neoplasia Date: 2019-02-11 Impact factor: 5.715